PlainBillCongress, translated.Legislation. Context. Public interest.
H.R.2606 / 108th Congress

Prescription Drug and Medicare Improvement Act of 2003

Referred to the Subcommittee on Health.

Official summary

Version 00 · Introduced in House · Jun 25, 2003

Prescription Drug and Medicare Improvement Act of 2003 - Amends title XVIII (Medicare) of the Social Security Act (SSA) to add a new part D (Voluntary Prescription Drug Benefit Delivery Program) (VPDBDP) under which each individual who is entitled to benefits under Medicare part A (Hospital Insurance) or enrolled under Medicare part B (Supplemental Medical Insurance) is entitled to obtain qualified prescription drug coverage. Authorizes the individual to elect to enroll: (1) in a MedicareAdvantage (MA) plan (replacing the current Medicare+Choice plans under Medicare part C (Medicare+Choice)); or (2) if a fee-for-service enrollee not in an MA plan, in a Medicare Prescription Drug (MPD) plan. Makes separate provision for: (1) enrollees in a MedicareAdvantage medical savings account (MSA) plan; and (2) enrollees in MedicareAdvantage private fee-for-service plans.

Makes the Administrator of the Center for Medicare Choices (CMC), established under this Act, responsible for administration of the VPDBDP.

Outlines standard coverage benefit packages for FY 2006. Includes for the standard package an annual deductible of $275, and requires insurers to cover 50 percent of enrollees drug costs up to the initial coverage limit of $4,500. Requires enrollees to cover all costs over $4,500 until out-of-pocket expenses reach $3,700 (catastrophic threshhold), after which an enrollee would be responsible only for a ten-percent co-pay. Prescribes a formula for adjustment of such deductible and annual limits for inflation. Establishes a bidding process for negotiating the terms and conditions of MPD plan sponsors. Provides for full premium subsidy and reduction of cost-sharing for individuals with incomes below 135 percent of the Federal poverty level. Establishes a Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund. Sets out a new Medicare prescription drug discount card and assistance program under the Medicare program. Directs the Secretary to develop or adopt standards for electronic prescribing transactions. Directs the Secretary to establish within the Department of Health and Human Services the CMC, which shall be separate from the Center for Medicare and Medicaid Services, including an Office of Beneficiary Assistance (containing a Medicare Ombudsman) and a Medicare Competitive Policy Advisory Board. Revises Medicare requirements with regard to: (1) part A concerning rural health care, inpatient hospital services, skilled nursing facility services, hospices, and the Federal rate for hospitals in Puerto Rico; (2) part B concerning physicians services and other specified services, as well as demonstration projects for coverage of chiropractic services, Medicare health care quality, Medicare complex clinical case management payment, and Medicare fee-for-service care coordination; and (3) part A and B concerning home health services, as well as a demonstration program for substitute adult day care services. Revises requirements with respect to regulatory procedures, the Medicare appeals process, contracting with Medicare administrative contractors, provider education, a Medicare Provider Ombudsman, beneficiary outreach demonstration programs, prepayment review, recovery of overpayments, enforcement, and establishment of a Consumer Ombudsman Account in the Federal Hospital Insurance Trust Fund. Greater Access to Affordable Pharmaceuticals Act - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with regard to: (1) the 30-month of Food and Drug Administration approval for any new drug in certain circumstances; and (2) forfeiture of the 180-day marketing exclusivity period by the first new drug applicant to a subsequent applicant. Amends the FFDCA to direct the Secretary of Health and Human Services to promulgate regulations permitting pharmacists, wholesalers, and individuals to import prescription drugs from Canada into the United States, subject to specified conditions.

Read the summary on Congress.gov
PlainBill analysis is coming later. This page presents official source data. We have not yet published a PlainBill explanation for this bill.

Who introduced it

Rep. Thompson, Mike [D-CA-1] · D–CA

Committees

  • Energy and Commerce Committee
  • Ways and Means Committee
21 cosponsorship records, including any withdrawals

Actions

A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.

  1. Referred to the Subcommittee on Health.

  2. Referred to the Subcommittee on Health.

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  4. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  6. Introduced in House

  7. Introduced in House

Bill text & related measures

Text links open the official source. We currently store references to these documents.

Related bills identified by Congress.gov

No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.

Source last updated: Aug 18, 2025. Consult Congress.gov for the current record.

Explore the bill from different angles

Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.

Neutral evidence review

Objective

Analyze H.R.2606 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.

View full prompt & sources
Fairness and public impact

Progressive lens

Examine H.R.2606 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.

View full prompt & sources
Institutions and government scope

Conservative lens

Examine H.R.2606 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.

View full prompt & sources
Individual rights and government power

Liberty lens

Examine H.R.2606 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.

View full prompt & sources